• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SPK Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    9/13/22 5:03:03 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials
    Get the next $SPK alert in real time by email
    0001848097 false --12-31 0001848097 2022-09-08 2022-09-08 0001848097 SPK:UnitsMember 2022-09-08 2022-09-08 0001848097 us-gaap:CommonStockMember 2022-09-08 2022-09-08 0001848097 us-gaap:RightsMember 2022-09-08 2022-09-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 8-K

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    September 13, 2022 (September 08, 2022)

    Date of Report (Date of earliest event reported)

     

    SPK Acquisition Corp.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-40462   86-1373795
    (State or other jurisdiction of
    incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    Room 368, 302 Buwei
    211 Fute North Road,
    China (Shanghai) Pilot Free Trade Zone, 200131
      n/a
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (86) 134-3912-9879

     

    N/A 

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒ Written communications pursuant to Rule 425 under the Securities Act
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
     Units, each Unit comprised of one share of Common Stock and one Right    SPKAU   THE NASDAQ Stock Market LLC
    Common Stock, par value $0.0001 per share   SPK   THE NASDAQ Stock Market LLC
    Rights, each to receive one-tenth of a share of Common Stock   SPKAR   THE NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

    Item 1.01 Entry into a Material Definitive Agreement

     

    As approved by its stockholders at the special meeting of Stockholders held on September 9, 2022 (the “Special Meeting”), SPK Acquisition Corp. (the “Company” or “SPK”) entered into an amendment to the amended and restated investment management trust agreement dated as of June 3, 2022, with Continental Stock Transfer & Trust Company, on September 9, 2022 (the “Trust Amendment”). Pursuant to the Trust Amendment, the Company has the right to extend the time to complete a business combination six (6) times for an additional one (1) month each time, from September 10, 2022, to March 10, 2023, by depositing $50,000 to the Company’s trust account for each one-month extension (each an “Extension”).

      

    On September 8, 2022, the Company entered into a subscription agreement with Varian Biopharmaceuticals, Inc., (“Varian”) and Alpha Capital Anstalt (“Alpha”), whereby SPK shall issue a $50,000 unsecured promissory note (an “Extension Note”), to each of Alpha and Varian, to fund the first and second month Extensions (the “Subscription Agreement”). Each Extension Note bears interest at the rate of 5% per annum, and both Extension Notes will be repaid upon the consummation of a business combination by the Company. The Subscription Agreement provided that Alpha would purchase the first Extension Note contemporaneously with the Subscription Agreement, to fund the first month Extension, and if the business combination has not been consummated by October 8, 2022, SPK will issue a second Extension Note to Varian on October 8, 2022, to fund the second month Extension.

     

    On September 8, 2022, the Company issued an Extension Note to Alpha in the amount of $50,000, pursuant to the Subscription Agreement. The Company deposited the $50,000 into the trust account on September 9, 2022, thereby extending the time to complete a business combination for one month, from September 10, 2022 to October 10, 2022.

     

    The foregoing description of the Subscription Agreement and Extension Note does not purport to be complete and is qualified in its entirety by the terms and conditions of the Subscription Agreement and Extension Note, the forms of which are filed hereto as Exhibit 10.1 and Exhibit 99.1, respectively, and are incorporated by reference herein.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information in Item 1.01 related to the Subscription Agreement and Extension Note are incorporated by reference into this Item 2.03.

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    As approved by its stockholders at the Meeting on September 9, 2022, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on September 9, 2022 (the “Charter Amendment”), giving the Company the right to extend the date by which it has to complete a business combination up to six (6) times for an additional one (1) month each time, from September 10, 2022 to March 10, 2023.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On September 9, 2022, the Company held the Special Meeting. On August 23, 2022, the record date for the Special Meeting, there were 6,596,275 shares of common stock of SPK entitled to be voted at the Special Meeting, 75.62% of which were represented in person or by proxy.

     

     

     

     

    The final results for each of the matters submitted to a vote of SPK’s stockholders at the Special Meeting are as follows:

     

    1. Charter Amendment

     

    Stockholders approved the proposal to amend the Company’s amended and restated certificate of incorporation, giving SPK the right to extend the date by which it has to complete a business combination six (6) times for an additional one (1) month each time, from September 10, 2022 to March 10, 2023. Adoption of the amendment required approval by the affirmative vote of at least a majority of the Company’s outstanding shares of common stock. The voting results were as follows:

     

    FOR  AGAINST  ABSTAIN  BROKER NON-VOTES
     4,633 ,395    354,600    0    0 

     

    2. Trust Amendment

     

    Stockholders approved the proposal to amend the Company’s amended and restated investment management trust agreement, dated as of June 3, 2022 by and between the Company and Continental Stock Transfer & Trust Company to allow the Company to extend the time it has to complete a business combination six (6) times for an additional one (1) month each time from September 10, 2022, to March 10, 2023 by depositing into the trust account $50,000 for each one-month Extension. Adoption of the amendment required approval by the affirmative vote of at least a majority of the Company’s outstanding shares of common stock. The voting results were as follows:

     

    FOR  AGAINST  ABSTAIN  BROKER NON-VOTES
     4,633 ,395    354,600    0    0 

      

    Item 8.01. Other Events.

     

    In connection with the stockholders’ vote at the Special Meeting of Stockholders held by SPK Acquisition Corp. on September 9, 2022, 4,052,916 shares were tendered for redemption.

     

    The Company extended the time it has to complete its initial business combination from September 10, 2022, to October 10, 2022 by depositing $50,000 to the trust account on September 9, 2022.

     

     

     

     

    Item 9.01. Financial Statements and Exhibits

     

    (c) Exhibits:

      

    Exhibit No.   Description
         
    1.1   Amendment to the amended and restated investment management trust agreement, dated as of June 3, 2022, between SPK Acquisition Corp. and Continental Stock Transfer & Trust Company dated September 9, 2022
    3.1   Amendment to the Amended and Restated Certificate of Incorporation of SPK Acquisition Corp., dated September 9, 2022
    10.1   Subscription Agreement, dated as of September 8, 2022 among SPK Acquisition Corp., Varian Biopharmaceuticals, Inc. and Alpha Capital Anstalt
    99.1   Promissory Note, dated as of September 8, 2022 from the Registrant to Alpha Capital Anstalt

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Dated: September 13, 2022 SPK ACQUISITION CORP.
       
      By: /s/ Sophie Tao
      Name: Sophie Tao
      Title: Chief Executive Officer

     

     

     

    Get the next $SPK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SPK
    SEC Filings

    View All

    SEC Form RW filed by SPK Acquisition Corp.

    RW - SPK Acquisition Corp. (0001848097) (Filer)

    12/29/22 5:30:35 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    SEC Form 25-NSE filed by SPK Acquisition Corp.

    25-NSE - SPK Acquisition Corp. (0001848097) (Subject)

    12/29/22 4:12:16 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    SPK Acquisition Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events (Amendment)

    8-K/A - SPK Acquisition Corp. (0001848097) (Filer)

    12/29/22 3:48:49 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    $SPK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Varian Biopharmaceuticals, Inc. and SPK Acquisition Corp. Announce Release of Investor Presentation Regarding Previously Announced Merger; Provide Corporate Update

    NAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a special purpose acquisition company ("SPAC"), today announced a joint presentation to discuss the proposed transaction and provide a corporate update. The presentation can be accessed by clicking the link here or by visiting Varian Bio's investor section of its website at www.varianbio.com.         Transaction Overview Pursuant to the merger agreement, Varian Bio will merge with a wholly owned subsidiary of SPK, with Varian Bio being the surviving

    2/28/22 5:29:23 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    Varian Biopharmaceuticals, Inc., a Precision Oncology Company, to Become Publicly Traded Through a Merger with SPK Acquisition Corp.

    Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a post-transaction pro forma equity value of approximately $116 million, assuming no redemptions from SPK's existing public shareholdersMerger expected to close in Q2 2022, and the combined company will be listed on NASDAQ under the proposed ticker symbol "VBIO" NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a spec

    2/14/22 9:00:00 AM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    $SPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Owl Creek Asset Management, L.P. disposed of $4,917,865 worth of shares (476,076 units at $10.33)

    4 - SPK Acquisition Corp. (0001848097) (Issuer)

    1/5/23 4:18:15 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    SEC Form 3: New insider Owl Creek Asset Management, L.P. claimed ownership of 476,076 shares

    3 - SPK Acquisition Corp. (0001848097) (Issuer)

    12/15/22 4:15:19 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    $SPK
    Financials

    Live finance-specific insights

    View All

    Varian Biopharmaceuticals, Inc., a Precision Oncology Company, to Become Publicly Traded Through a Merger with SPK Acquisition Corp.

    Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a post-transaction pro forma equity value of approximately $116 million, assuming no redemptions from SPK's existing public shareholdersMerger expected to close in Q2 2022, and the combined company will be listed on NASDAQ under the proposed ticker symbol "VBIO" NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a spec

    2/14/22 9:00:00 AM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    $SPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SPK Acquisition Corp. (Amendment)

    SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)

    2/14/23 12:25:59 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by SPK Acquisition Corp. (Amendment)

    SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)

    2/14/23 9:41:33 AM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by SPK Acquisition Corp. (Amendment)

    SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)

    2/13/23 4:02:03 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials